Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221
Metrics: PDF 1099 views | HTML 1130 views | ?
Natalie Falkenberg1, Nataša Anastasov2, Annalisa Schaub1, Vanja Radulovic2, Manfred Schmitt3, Viktor Magdolen3 and Michaela Aubele1
1 Institute of Pathology, German Research Center for Environmental Health, Neuherberg, Germany
2 Institute of Radiation Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
3 Clinical Research Unit, Department of Obstetrics and Gynecology, Technische Universität München, München, Germany
Natalie Falkenberg, email:
Keywords: therapy, microRNA, miR-222, PLAUR, soluble
Received: November 20, 2014 Accepted: February 03, 2015 Published: March 10, 2015
miR-221/-222 and components of the urokinase-type plasminogen activator system (uPAS) are associated with metastasis and poor prognosis in breast cancer, including the triple-negative subtype (TNBC). Modification of components of uPAS and involved miRNAs may contribute to targeted therapy for breast cancer patients. miR-221-/-222-overexpressing or miR-221-depleted cells were employed for qRT-PCR and Western blots to show associations of uPAR with miR-221/-222. To substantiate direct targeting of miR-221/-222 within 3’ UTR of the uPAR isoform 2, in silico analysesand in vitro assays were conducted. Significant associations between miR-221 and uPAR isoform 2 expressions were observed at the mRNA and protein levels in breast cancer cells representing TNBC. For the first time, the uPAR isoform 2 was demonstrated as direct target for miR-221/-222. Inhibition of miR-221 reduced uPAR protein expression and expression of the tumor cell invasion markers vimentin and RHOC. These results demonstrate a direct and positive regulation of the secreted uPAR isoform 2 by miR-221, increasing its protein expression, a prerequisite for malignancy, while the other uPAR isoforms (1, 3 and 4) are indirectly regulated through miR-10b and miR-221/-222. By targeting uPAR isoforms and/or miRNA-221/-222, the diagnosis and therapy of breast cancer, in particular in TNBC, could be significantly improved.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.